{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:37:26Z","timestamp":1775032646408,"version":"3.50.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the most common fatal malignancy among men and a major cause of cancer-related death. Apalutamide, a second-generation androgen receptor inhibitor, is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). However, an increasing number of potentially life-threatening severe cutaneous adverse reactions (SCARs) associated with apalutamide have raised clinical concerns. This review aims to characterize apalutamide-induced SCARs and summarize effective management strategies based on reported cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Europe PMC, and CNKI for case reports of SCARs associated with apalutamide. Keywords included \u201cApalutamide\u201d and \u201cDrug eruptions.\u201d A total of 18 cases were identified and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We reviewed the clinical characteristics and treatment of 3 cases of DRESS, 14 cases of SJS\/TEN, and 1 case of AGEP, all highly suspected to be caused by apalutamide, reported globally. The most frequent SCARs associated with apalutamide are SJS\/TEN. The median onset time of SCARs in these cases was 39.5\u00a0days, significantly shorter than the onset time of rash in phase III clinical trials of apalutamide. Geographically, the majority of reported cases originated from East Asia. By analyzing the treatment regimens and clinical outcomes of these patients, combined with a literature review, we proposed a set of definitive therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Apalutamide-induced SCARs tend to occur earlier than common rashes observed in clinical trials, with a predominance of reported cases in East Asian populations. Immediate discontinuation of the suspected drug is the cornerstone of SCAR management. Supportive care, systemic corticosteroids, intravenous immunoglobulin (IVIG), cyclosporine, plasmapheresis, and TNF-\u03b1 antagonists play important roles in treatment. Personalized dosing strategies based on body weight or body surface area, along with proactive rash management, may help mitigate risk and optimize therapeutic continuity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1769981","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:31Z","timestamp":1775022211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Apalutamide-induced severe cutaneous adverse reactions in prostate cancer: a comprehensive review of reported cases and clinical strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Taisong","family":"Wang","sequence":"first","affiliation":[{"name":"Southwest Medical University School of Clinical Medical Sciences","place":["Luzhou, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renbin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Southwest Medical University School of Clinical Medical Sciences","place":["Luzhou, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/jjco\/hyaf082","article-title":"Skin rash induced by apalutamide correlated with age and relative dose intensity adjusted by body surface area in Japanese patients with prostate cancer","volume":"55","author":"Akagi","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40487-024-00290-7","article-title":"Early identification and management of patients with rash on apalutamide","volume":"12","author":"Birtle","year":"2024","journal-title":"Oncol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/cod.14024","article-title":"The first case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by apalutamide, a novel oral androgen receptor antagonist","volume":"86","author":"Ducharme","year":"2022","journal-title":"Contact Dermat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs [published correction appears in Lancet. 2017 Oct 28;390(10106):1948]","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1111\/1346-8138.15510","article-title":"Fatal case of toxic epidermal necrolysis due to apalutamide used as a novel prostate cancer drug","volume":"47","author":"Endo","year":"2020","journal-title":"J. Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa181567","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1159\/000532009","article-title":"Apalutamide-induced toxic epidermal necrolysis in a caucasian patient with metastatic castration-sensitive prostate cancer: a case report and review of the literature","volume":"16","author":"Flynn","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study","volume":"42","author":"Han","year":"2017","journal-title":"J. Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/iju5.12525","article-title":"Acute generalized exanthematous pustulosis during Apalutamide treatment in a patient with prostate cancer","volume":"5","author":"Honda","year":"2022","journal-title":"IJU Case Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1111\/jdv.18660","article-title":"Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome\/toxic epidermal necrolysis related to Apalutamide","volume":"37","author":"Hsu","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"B15","volume-title":"Toxic epidermal necrolysis associated with Apalutamide: a case report and brief review of the literatures","author":"Huang","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD013130","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","article-title":"Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model","volume":"33","author":"Ji","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm. Venereol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.burns.2021.11.004","article-title":"Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in toxic epidermal necrolysis, Steven-Johnsons syndrome, and TEN\/SJS overlap - metanalysis and metaregression of observational studies","volume":"48","author":"Krajewski","year":"2022","journal-title":"Burns"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1111\/1346-8138.16248","article-title":"Plasmapheresis as a promising treatment option in Apalutamide-associated toxic epidermal necrolysis","volume":"49","author":"Miyagawa","year":"2022","journal-title":"J. Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4009\/jsdt.55.29","article-title":"A case of apalutamide\u2012induced toxic epidermal necrolysis that was treated with plasma exchange","volume":"55","author":"Oda","year":"2022","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"B28","doi-asserted-by":"publisher","first-page":"adv00723","DOI":"10.2340\/actadv.v102.2243","article-title":"Toxic epidermal necrolysis caused by apalutamide: a case report of treatment using etanercept with conventional steroid therapy","volume":"102","author":"Osawa","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.mcna.2021.04.001","article-title":"Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis)","volume":"105","author":"Owen","year":"2021","journal-title":"Med. Clin. North Am."},{"key":"B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J. Burn Care Rehabil."},{"key":"B31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cia2.12138","article-title":"A case of toxic epidermal necrolysis associated with Apalutamide administration","volume":"3","author":"Sagawa","year":"2020","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/iju.14860","article-title":"Impact of body size on skin-related adverse events in advanced prostate cancer treated with Apalutamide: a multicenter retrospective study","volume":"29","author":"Sasaki","year":"2022","journal-title":"Int. J. Urol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1542\/peds.107.1.e14","article-title":"Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin","volume":"107","author":"Scheuerman","year":"2001","journal-title":"Pediatrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/all.15608","article-title":"Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: diverse effects on systemic inflammation","volume":"78","author":"Schmidt","year":"2023","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","article-title":"Use of cyclosporine for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Shah","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41391-024-00858-4","article-title":"Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study","volume":"28","author":"Shore","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.clgc.2024.102250","article-title":"Dose per body weight predicts incidence and severity of Apalutamide-Related skin rash in metastatic castration-sensitive prostate cancer","volume":"23","author":"Suzuki","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","article-title":"Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan urological consortium","volume":"27","author":"Tohi","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of Apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/iju.14447","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: a subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study","volume":"28","author":"Uemura","year":"2021","journal-title":"Int. J. Urol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/iju.14843","article-title":"Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study","volume":"29","author":"Uemura","year":"2022","journal-title":"Int. J. Urol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1291564","DOI":"10.3389\/fimmu.2023.1291564","article-title":"Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.073","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management","volume":"90","author":"Wei","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/ddg.15150","article-title":"Toxic epidermal necrolysis post Apalutamide with preceding tislelizumab administration in a patient with two cancers","volume":"21","author":"Wu","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ajd.12318","article-title":"A 13-year retrospective study evaluating the efficacy of using air-fluidised beds for toxic epidermal necrolysis patients","volume":"57","author":"Xia","year":"2016","journal-title":"Australas. J. Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol. Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.19960\/j.issn.1005-0698.202310013","article-title":"A case of toxic epidermal necrolysis associated with apalutamide administration","volume":"32","author":"Yana","year":"2023","journal-title":"Chin. J. Pharmacoepidemiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jaad.2020.02.069","article-title":"Cyclosporine for treatment of acute generalized exanthematous pustulosis: a retrospective analysis","volume":"83","author":"Yanes","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0165933","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"750173","DOI":"10.3389\/fphar.2021.750173","article-title":"Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens-Johnson Syndrome\/Toxic epidermal necrolysis: a propensity-matched retrospective Study in China","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/CCID.S378106","article-title":"Effectiveness and safety of early short-course, Moderate-to high-dose glucocorticoids for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a retrospective study","volume":"15","author":"Ye","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"758354","DOI":"10.3389\/fmed.2021.758354","article-title":"Case report: successful treatment of acute generalized exanthematous pustulosis with secukinumab","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1510583","DOI":"10.3389\/fphar.2025.1510583","article-title":"Liquid chromatography-tandem mass spectrometry assay for the simultaneous determination of apalutamide and its active metabolite N-desmethyl apalutamide, and its application in real-world patients with castration-resistant prostate cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1769981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:34Z","timestamp":1775022214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1769981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":64,"alternative-id":["10.3389\/fphar.2026.1769981"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1769981","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1769981"}}